BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 23708657)

  • 1. Identification of novel TMPRSS2:ERG mechanisms in prostate cancer metastasis: involvement of MMP9 and PLXNA2.
    Tian TV; Tomavo N; Huot L; Flourens A; Bonnelye E; Flajollet S; Hot D; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncogene; 2014 Apr; 33(17):2204-14. PubMed ID: 23708657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of TMPRSS2-ERG mechanisms in prostate cancer invasiveness: Involvement of MMP-9 and plexin B1.
    Liu B; Gu X; Huang T; Luan Y; Ding X
    Oncol Rep; 2017 Jan; 37(1):201-208. PubMed ID: 28004109
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer.
    Hermans KG; Boormans JL; Gasi D; van Leenders GJ; Jenster G; Verhagen PC; Trapman J
    Clin Cancer Res; 2009 Oct; 15(20):6398-403. PubMed ID: 19825963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TMPRSS2-ERG fusion promotes prostate cancer metastases in bone.
    Deplus R; Delliaux C; Marchand N; Flourens A; Vanpouille N; Leroy X; de Launoit Y; Duterque-Coquillaud M
    Oncotarget; 2017 Feb; 8(7):11827-11840. PubMed ID: 28055969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal expression of the ERG transcription factor in prostate cancer cells activates osteopontin.
    Flajollet S; Tian TV; Flourens A; Tomavo N; Villers A; Bonnelye E; Aubert S; Leroy X; Duterque-Coquillaud M
    Mol Cancer Res; 2011 Jul; 9(7):914-24. PubMed ID: 21669963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rational basis for the combination of PCA3 and TMPRSS2:ERG gene fusion for prostate cancer diagnosis.
    Robert G; Jannink S; Smit F; Aalders T; Hessels D; Cremers R; Mulders PF; Schalken JA
    Prostate; 2013 Jan; 73(2):113-20. PubMed ID: 22674214
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens].
    Xiao L; Zhu XZ; Wang Y; Gong Y; Guo CC
    Zhonghua Bing Li Xue Za Zhi; 2011 Jun; 40(6):392-6. PubMed ID: 21914348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TMPRSS2:ERG gene fusion expression regulates bone markers and enhances the osteoblastic phenotype of prostate cancer bone metastases.
    Delliaux C; Tian TV; Bouchet M; Fradet A; Vanpouille N; Flourens A; Deplus R; Villers A; Leroy X; Clézardin P; de Launoit Y; Bonnelye E; Duterque-Coquillaud M
    Cancer Lett; 2018 Dec; 438():32-43. PubMed ID: 30201302
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TMPRSS2/ERG fusion gene expression alters chemo- and radio-responsiveness in cell culture models of androgen independent prostate cancer.
    Swanson TA; Krueger SA; Galoforo S; Thibodeau BJ; Martinez AA; Wilson GD; Marples B
    Prostate; 2011 Oct; 71(14):1548-58. PubMed ID: 21394739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort.
    Demichelis F; Fall K; Perner S; Andrén O; Schmidt F; Setlur SR; Hoshida Y; Mosquera JM; Pawitan Y; Lee C; Adami HO; Mucci LA; Kantoff PW; Andersson SO; Chinnaiyan AM; Johansson JE; Rubin MA
    Oncogene; 2007 Jul; 26(31):4596-9. PubMed ID: 17237811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion.
    Perner S; Mosquera JM; Demichelis F; Hofer MD; Paris PL; Simko J; Collins C; Bismar TA; Chinnaiyan AM; De Marzo AM; Rubin MA
    Am J Surg Pathol; 2007 Jun; 31(6):882-8. PubMed ID: 17527075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of dutasteride in pre-clinical ETS fusion-positive prostate cancer models.
    Ateeq B; Vellaichamy A; Tomlins SA; Wang R; Cao Q; Lonigro RJ; Pienta KJ; Varambally S
    Prostate; 2012 Oct; 72(14):1542-9. PubMed ID: 22415461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer.
    Winnes M; Lissbrant E; Damber JE; Stenman G
    Oncol Rep; 2007 May; 17(5):1033-6. PubMed ID: 17390040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of steroid and peptide hormone receptors, metabolic enzymes and EMT-related genes in prostate tumors in relation to the presence of the TMPRSS2/ERG fusion.
    Gerashchenko GV; Mevs LV; Chashchina LI; Pikul MV; Gryzodub OP; Stakhovsky EO; Kashuba VI
    Exp Oncol; 2018 Jun; 40(2):101-108. PubMed ID: 29949537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined analysis of TMPRSS2-ERG and TERT for improved prognosis of biochemical recurrence in prostate cancer.
    Sabaliauskaite R; Jarmalaite S; Petroska D; Dasevicius D; Laurinavicius A; Jankevicius F; Lazutka JR
    Genes Chromosomes Cancer; 2012 Aug; 51(8):781-91. PubMed ID: 22505341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
    Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
    Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1.
    Meisel Sharon S; Pozniak Y; Geiger T; Werner H
    Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genome-wide linkage analysis of TMPRSS2-ERG fusion in familial prostate cancer.
    Hofer MD; Kuefer R; Maier C; Herkommer K; Perner S; Demichelis F; Paiss T; Vogel W; Rubin MA; Hoegel J
    Cancer Res; 2009 Jan; 69(2):640-6. PubMed ID: 19147579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relation of ETS transcription factor family member ERG, androgen receptor and topoisomerase 2β expression to TMPRSS2-ERG fusion status in prostate cancer.
    Kolar Z; Burdova A; Jamaspishvili T; Bouchal J; Kucerova R; Bienova M; Kral M; Student V
    Neoplasma; 2014; 61(1):9-16. PubMed ID: 24195515
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predisposition for TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
    Luedeke M; Linnert CM; Hofer MD; Surowy HM; Rinckleb AE; Hoegel J; Kuefer R; Rubin MA; Vogel W; Maier C
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3030-5. PubMed ID: 19861517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.